+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global CAR T-cell Therapy Market 2018-2022 - Product Image

Global CAR T-cell Therapy Market 2018-2022

  • ID: 4650750
  • Report
  • September 2018
  • Region: Global
  • 112 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • bluebird bio
  • CARsgen Therapeutics
  • Celgene
  • Gilead
  • Novartis
  • MORE
About CAR T-cell Therapy

Chimeric antigen receptor (CAR) is one of the recent innovations in the pharmaceutical industry for the treatment of serious, life-threatening diseases, typically in the areas of oncology. CARs are engineered receptors to attack cancer cells. In this therapy, patients’ T-cells are modified to attack cancer cells. In this therapy, patients’ T-cells are modified in the laboratory to fight against various cancer indications.

The analysts forecast the Global CAR T-cell Therapy Market to grow at a CAGR of 63.15% during the period 2018-2022.

Covered in this report
The report covers the present scenario and the growth prospects of the CAR T-cell therapy market. To calculate the market size, the report considers the revenue generated from the application of CAR T-cell therapy across the globe.

The market is divided into the following segments based on geography:
  • Americas
  • APAC
  • EMEA
The report, CAR T-cell therapy market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • bluebird bio
  • CARsgen Therapeutics
  • Celgene
  • Gilead
  • Novartis
Market drivers
  • Proven effectiveness of CAR T-cell therapy
  • For a full, detailed list, view the full report
Market challenges
  • High cost of CAR T-cell therapy
  • For a full, detailed list, view the full report
Market trends
  • Collaborative R&D efforts
  • For a full, detailed list, view the full report
Key questions answered in this report
  • What will the market size be in 2022 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?
You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • bluebird bio
  • CARsgen Therapeutics
  • Celgene
  • Gilead
  • Novartis
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 05: MARKET SIZING
  • Market definition
  • Market sizing 2017
  • Market size and forecast 2017-2022
PART 06: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 07: PIPELINE

PART 08: MARKET SEGMENTATION BY ANTIGEN
  • Segmentation by antigen
  • Comparison by antigen
  • CD19 – Market size and forecast 2017-2022
  • CD22 – Market size and forecast 2017-2022
  • Others – Market size and forecast 2017-2022
  • Market opportunity by antigen
PART 09: CUSTOMER LANDSCAPE

PART 10: REGIONAL LANDSCAPE
  • Geographical segmentation
  • Regional comparison
  • Americas – Market size and forecast 2017-2022
  • EMEA – Market size and forecast 2017-2022
  • APAC – Market size and forecast 2017-2022
  • Key leading countries
  • Market opportunity
PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 13: MARKET TRENDS
  • Collaborative R&D efforts
  • Reimbursement coverage
  • Advent of armored CAR T-cells
PART 14: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
PART 15: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • bluebird bio
  • CARsgen Therapeutics
  • Celgene
  • Gilead
  • Novartis
PART 16: APPENDIX
  • List of abbreviations
List of Exhibits
Exhibit 01: Parent market: Global regenerative medicines market
Exhibit 02: Global regenerative medicines market segmentation
Exhibit 03: Market characteristics: Overview
Exhibit 04: Market segments
Exhibit 05: CAR T-cell therapy process
Exhibit 06: CAR T-cell therapy – Market overview
Exhibit 07: Market definition - Inclusions and exclusions checklist
Exhibit 08: Market size 2017
Exhibit 09: Validation techniques employed for market sizing 2017
Exhibit 10: Global CAR T-cell therapy market – Market size and forecast 2017-2022 ($ mn)
Exhibit 11: Global CAR T-cell therapy market – Year-over-year growth 2018-2022 (%)
Exhibit 12: Five forces analysis 2017
Exhibit 13: Five forces analysis 2022
Exhibit 14: Bargaining power of buyers
Exhibit 15: Bargaining power of suppliers
Exhibit 16: Threat of new entrants
Exhibit 17: Threat of substitutes
Exhibit 18: Threat of rivalry
Exhibit 19: Market condition - Five forces 2017
Exhibit 20: Major indications covered under CAR T-cell therapy R&D landscape
Exhibit 21: Global CAR T-cell therapy market pipeline: Overview
Exhibit 22: CAR T-cell therapy pipeline: Overview
Exhibit 23: Global CAR T-cell therapy market – Market share by antigen 2017-2022 (%)
Exhibit 24: Comparison by antigen
Exhibit 25: Global CAR T-cell therapy market by CD19 – Market size and forecast 2017-2022 ($ mn)
Exhibit 26: Global CAR T-cell therapy market by CD19 – Year-over-year growth 2018-2022 (%)
Exhibit 27: Global CAR T-cell therapy market by CD22 – Market size and forecast 2017-2022 ($ mn)
Exhibit 28: Global CAR T-cell therapy market by CD22 – Year-over-year growth 2018-2022 (%)
Exhibit 29: Global CAR T-cell therapy market by others – Market size and forecast 2017-2022 ($ mn)
Exhibit 30: Other antigens: Overview
Exhibit 31: Global CAR T-cell therapy market by others – Year-over-year growth 2018-2022 (%)
Exhibit 32: Market opportunity by antigen
Exhibit 33: Customer landscape
Exhibit 34: Global CAR T-cell therapy – Market share by geography 2017-2022 (%)
Exhibit 35: Regional comparison
Exhibit 36: CAR T-cell therapy market in Americas – Market size and forecast 2017-2022 ($ mn)
Exhibit 37: CAR T-cell therapy market in Americas – Overview
Exhibit 38: CAR T-cell therapy market in Americas – Year-over-year growth 2018-2022 (%)
Exhibit 39: CAR T-cell therapy market in EMEA – Market size and forecast 2017-2022 ($ mn)
Exhibit 40: CAR T-cell therapy market in EMEA – Overview
Exhibit 41: CAR T-cell therapy market in EMEA – Year-over-year growth 2018-2022 (%)
Exhibit 42: CAR T-cell therapy market in APAC – Market size and forecast 2017-2022 ($ mn)
Exhibit 43: CAR T-cell therapy market in APAC – Overview
Exhibit 44: CAR T-cell therapy market in APAC – Year-over-year growth 2018-2022 (%)
Exhibit 45: Key leading countries: Overview
Exhibit 46: Market opportunity
Exhibit 47: Segmentation of therapies in research based on tumor type
Exhibit 48: Vendor landscape
Exhibit 49: Landscape disruption
Exhibit 50: Vendors covered: Overview
Exhibit 51: Vendor classification: Overview
Exhibit 52: Market positioning of vendors: Overview
Exhibit 53: bluebird bio – Overview
Exhibit 54: bluebird bio – Business segments
Exhibit 55: bluebird bio – Organizational developments
Exhibit 56: bluebird bio – Key offerings
Exhibit 57: bluebird bio – Key customers
Exhibit 58: CARsgen Therapeutics – Overview
Exhibit 59: CARsgen Therapeutics – Business segments
Exhibit 60: CARsgen Therapeutics – Organizational developments
Exhibit 61: CARsgen Therapeutics – Key offerings
Exhibit 62: CARsgen Therapeutics – Key customers
Exhibit 63: Celgene – Overview
Exhibit 64: Celgene – Business segments
Exhibit 65: Celgene – Organizational developments
Exhibit 66: Celgene – Geographic focus
Exhibit 67: Celgene – Key offerings
Exhibit 68: Celgene – Key customers
Exhibit 69: Gilead – Overview
Exhibit 70: Gilead – Business segments
Exhibit 71: Gilead – Organizational developments
Exhibit 72: Gilead – Geographic focus
Exhibit 73: Gilead – Key offerings
Exhibit 74: Gilead – Key customers
Exhibit 75: Novartis – Overview
Exhibit 76: Novartis – Business segments
Exhibit 77: Novartis – Organizational developments
Exhibit 78: Novartis – Geographic focus
Exhibit 79: Novartis – Segment focus
Exhibit 80: Novartis – Key offerings
Exhibit 81: Novartis – Key customers
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • bluebird bio
  • CARsgen Therapeutics
  • Celgene
  • Gilead
  • Novartis
  • MORE
Global CAR T-cell Therapy Market 2018-2022

The author of the report recognizes the following companies as the key players in the global CAR T-cell therapy market: bluebird bio, CARsgen Therapeutics, Celgene, Gilead, and Novartis.
Commenting on the report, an analyst from the research team said: “One trend affecting this market is the collaborative R&D efforts. In the past few years, the market has witnessed several research institutions, biotechnology companies, and pharmaceutical players collaborating for the research of CAR T-cell therapies.”

According to the report, one driver influencing this market is the proven effectiveness of CAR T-cell therapy. CAR T-cell therapies are proven to have higher efficacy than the other therapies that are currently available in the market for treatment of cancer.

Further, the report states that one challenge affecting this market is the high cost of CAR T-cell therapy. The high costs associated with CAR T-cell therapy is one of the biggest challenge for the growth of the market.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • bluebird bio
  • CARsgen Therapeutics
  • Celgene
  • Gilead
  • Novartis
Note: Product cover images may vary from those shown
Adroll
adroll